Breast cancer stem cells, heterogeneity, targeting therapies and therapeutic implications

Zeng，Xiaobin1,2; Liu，Chengxiao1; Yao，Jie1; Wan，Haoqiang1,2,3; Wan，Guoqing4; Li，Yingpeng3; Chen，Nianhong1,5,6

2021

10.1016/j.phrs.2020.105320

PHARMACOLOGICAL RESEARCH   影响因子和分区

1043-6618

DBoth hereditary and sporadic breast cancer are suggested to develop from a stem cell subcomponent retaining most key stem cell properties but with dysregulation of self-renewal pathways, which drives tumorigenic differentiation and cellular heterogeneity. Cancer stem cells (CSCs), characterized by their self-renewal and differentiation potential, have been reported to contribute to chemo-/radio-resistance and tumor initiation and to be the main reason for the failure of current therapies in breast cancer and other CSC-bearing cancers. Thus, CSC-targeted therapies, such as those inducing CSC apoptosis and differentiation, inhibiting CSC self-renewal and division, and targeting the CSC niche to combat CSC activity, are needed and may become an important component of multimodal treatment. To date, the understanding of breast cancer has been extended by advances in CSC biology, providing more accurate prognostic and predictive information upon diagnosis. Recent improvements have enhanced the prospect of targeting breast cancer stem cells (BCSCs), which has shown promise for increasing the breast cancer remission rate. However, targeted therapy for breast cancer remains challenging due to tumor heterogeneity. One major challenge is determining the CSC properties that can be exploited as therapeutic targets. Another challenge is identifying suitable BCSC biomarkers to assess the efficacy of novel BCSC-targeted therapies. This review focuses mainly on the characteristics of BCSCs and the roles of BCSCs in the formation, maintenance and recurrence of breast cancer; self-renewal signaling pathways in BCSCs; the BCSC microenvironment; potential therapeutic targets related to BCSCs; and current therapies and clinical trials targeting BCSCs.

Breast cancer stem cell Breast cancer therapy Cancer heterogeneity Ubiquitination

SCI

英语

ESI高被引

第一 ; 通讯

Natural Science Foundation of China[81503221,81703939] ; Science and Technology Planning Project of Shenzhen Municipality["JCYJ20170307095556333","JCYJ20170413093108233","JCYJ20170307100726777"] ; Natural Science Foundation of Guangdong Province["2017A030313659","2014A030310365"]

Pharmacology & Pharmacy

Pharmacology & Pharmacy

WOS:000609226800066

ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD

PHARMACOLOGY & TOXICOLOGY

Web of Science

1.Center Lab of Longhua Branch and Department of Infectious Disease,Shenzhen People's Hospital,The Second Clinical Medical College,Jinan University,The First Affiliated Hospital,Southern University of Science and Technology,Shenzhen,518020,China
2.Guangdong Provincial Key Laboratory of Regional Immunity and Diseases,Medicine School of Shenzhen University,Shenzhen,518037,China
3.Department of Gastroenterology,(Longhua Branch),Shenzhen People's Hospital,2nd Clinical Medical College of Jinan University,Shenzhen,518120,China
4.Shanghai University of Medicine and Health Sciences Affiliated Zhoupu Hospital,Shanghai,201318,China
5.Department of Cell Biology & University of Pittsburgh Cancer Institute,School of Medicine,University of Pittsburgh,15261,United States
6.Laboratory of Signal Transduction,Department of Radiation Oncology,Memorial Sloan-Kettering Cancer Center,New York,10065,United States

Zeng，Xiaobin,Liu，Chengxiao,Yao，Jie,et al. Breast cancer stem cells, heterogeneity, targeting therapies and therapeutic implications[J]. PHARMACOLOGICAL RESEARCH,2021,163.

Zeng，Xiaobin.,Liu，Chengxiao.,Yao，Jie.,Wan，Haoqiang.,Wan，Guoqing.,...&Chen，Nianhong.(2021).Breast cancer stem cells, heterogeneity, targeting therapies and therapeutic implications.PHARMACOLOGICAL RESEARCH,163.

Zeng，Xiaobin,et al."Breast cancer stem cells, heterogeneity, targeting therapies and therapeutic implications".PHARMACOLOGICAL RESEARCH 163(2021).